ScholarX: PARK, WOONG YANG

Detailed Information

PARK, WOONG YANG (박웅양)

Medicine (Medicine)

Research Area

Tel 02-3410-6128
Homepage

ResearcherID ORCiD Scopus Google Scholar ID ResearchGate

Keyword

Next generation sequencing:6||breast cancer:5||tumor microenvironment:5||Circulating tumor DNA:5||Immunotherapy:5||Polygenic risk score:5||singlecell RNA sequencing:5||Nextgeneration sequencing:4||Biomarker:4||COVID19:4||inflammation:4||Whole exome sequencing:3||Cochlear implantation:3||deafness:3||Ataxia:3||Radiotherapy:3||pneumonia:3||nonsmall cell lung cancer:3||TP53:3||s disease:3||targeted deep sequencing:3||Liquid biopsy:3||DNA methylation:3||Precision medicine:3||Targeted deep sequencing:3||mutation:3||Mutation:3||nextgeneration sequencing:3||SARSCoV2:3||Tumor heterogeneity:3||RNA sequencing:3||Tumor mutation burden:3||autoimmune:2||NSCLC:2||prognostic marker:2||Ciliopathy:2||Caroli disease:2||Nephronophthisis 13:2||Dravet syndrome:2||Prognosis:2||Lung neoplasms:2||reimbursement:2||cancer:2||renal cell carcinoma:2||immune checkpoint inhibitor:2||Biomarkers:2||Hepatocellular carcinoma:2||Targeted exome sequencing:2||Dystonia:2||MYO15A:2||immunotherapy:2||Targeted sequencing:2||Targeted therapy:2||interstitial cystitis:2||RNAseq:2||EGFR:2||DFNB8/10:2||Receptor:2||Regorafenib:2||lymphoma:2||Treatment resistance:2||targeted therapy:2||macrophage:2||Cellfree DNA:2||Cancer genomics:2||DFNX2:2||IFNa:2||IL12p40:2||cochlear implantation:2||Genetic diagnosis:2||colorectal cancer:2||transcriptome analysis:2||Tumor microenvironment:2||tumor:2||Colorectal cancer:2||Genetic risk:2||Breast cancer:2||Tumour mutation burden:2||Tyrosine kinase inhibitor:2||molecular genetics:2||PDL1:2||Immunology:2||whole exome sequencing (WES):2||wholeexome sequencing:2||doxorubicin:2||Agerelated hearing loss:2||#8208:2||moyamoya disease:2||multiple myeloma:2||POU3F4:2||Wholeexome sequencing:2||Wholegenome sequencing:2||Incomplete partition type III:2||Environmental factor:2||Molecular diagnosis:2||Palbociclib:2||Singlecell RNA sequencing:2||Genomic profile:2||adenocarcinoma:2||Congenital hepatic fibrosis:2||gammadelta T cells:2||Molecular targeted therapy:2||Patientderived cells:2||Copy number variation:2||Glioblastoma:2||De novo:2||Epilepsy gene panel:2||genetic analysis:2||Deafness:2||personalized medicine:2||ALK:2||policy framework:2||Deletion:2||HER2:2||NGS:2||genomics:2||Lifestyle:2||Adenocarcinoma:2||FGFR2 amplification:1||FLT3 amplification:1||Familial case:1||Fibrosis:1||Follicular peripheral Tcell lymphoma:1||Founder effect:1||GJB2:1||GNAL:1||GWAS:1||Gastric cancer:1||Gene expression profiling:1||Genetic:1||Genetic heterogeneity:1||Genetic network:1||Genetic risk score:1||Genetics:1||Genomewide association study:1||Genomic analysis:1||Genomics:1||Gleason score:1||Glioma:1||Gnai1:1||Gout:1||Gynecologic malignancy:1||HER pathway:1||HER2 expression:1||HER2 mutation:1||HER2positive:1||HM61713:1||Head and neck cancer:1||Health:1||Hearing loss:1||Hepatorenal fibrocystic disease:1||Hereditary:1||Homologous recombination repair deficiengy (HRD):1||Human cognition:1||Human epidermal growth factor receptor 2 (HER2):1||Human papillomavirus:1||ID2:1||IRF4:1||IgM:1||Imaging genomics:1||Immune activation:1||Immune checkpoint inhibitor:1||Immunohistochemistry:1||Immunotherapic biomarker:1||Infection biology:1||Inherited retinal degeneration:1||Innate immunity:1||International classification of diseases:1||Intestinal Organoid:1||Intestinal Stem Cell:1||Intratumoral heterogeneity:1||Kim type:1||Knowledgebase:1||Korea:1||Korean:1||Labonadisc:1||Linkage analy:1||LoeysDietz syndrome:1||Long survival outcomes:1||Lung cancer:1||Lysosomal storage disease:1||MAPK pathway:1||MMIA:1||MYCN:1||MYCN nonamplified neuroblastoma:1||MYO6:1||Machine learning:1||Macrophage differentiation:1||Macrophages:1||Macular dystrophy:1||Mathematical representation:1||Mendelian:1||Mendelian randomization:1||Messenger RNA:1||Met:1||Metachromatic leukodystrophy:1||Metastatic breast cancer (MBC):1||Metastatic cancer:1||Methotrexate:1||Microbeads:1||Mn porphyrin clinical candidate:1||MnBuOE):1||MnTnBuOE2PyP<sup>5+</sup> (BMX001:1||Mobile Application:1||Molecular genetic test:1||Molecular screening:1||Molecular sequencing:1||Multiomics:1||Multicentric:1||Multiple congenital anomalies:1||Muscleinvasive urothelial bladder cancer:1||MutL homolog 1 (MLH1):1||Mutational signature:1||Nacetylcysteine:1||NEU1 gene:1||NK:1||NPPC:1||NSSNHL:1||NTRK1 rearrangement:1||Neoadjuvant therapy:1||Network analysis:1||Neuroblastoma:1||NextGeneration Sequencing:1||Ninj1 protein:1||No conflicts of interest were declared:1||Nodal peripheral Tcell lymphoma with T follicular helper phenotype:1||NonHodgkin lymphoma:1||Nonsmallcell lung:1||Non–small cell lung cancer:1||Non–smallcell lung cancer (NSCLC):1||Novel mutation:1||Null distribution:1||Nutrition Assessment:1||OTOA:1||OTOF:1||Obesity:1||Osimertinib:1||Ovarian epithelial cancer:1||PARK:1||PARP inhibitor:1||PAX3:1||PCRbased:1||PDGFRA:1||PIK3CA:1||POLD1:1||PPI:1||PROM1:1||PRPS1:1||Pancreatic ductal adenocarcinoma:1||Paraneoplastic neuromyelitis optica:1||Pathogenic variant:1||Patientderived cell:1||Patientderived xenograft:1||Patientderived xenograft model:1||Peripheral Tcell lymphoma:1||Peripheral Tcell lymphomaNOS:1||Permutation:1||Pharmacogenomic analysis:1||Pharmacogenomics:1||Phenomewide association study:1||Phenotype:1||Plasma DNA:1||Platinum compound:1||Pleiotropy:1||Pol delta:1||Polymorphism, Genetic:1||Positron emission tomography (PET):1||Precision oncology:1||Prediction and validation:1||Primary CNS lymphoma:1||Prognosis prediction:1||Programmed Cell Death 1 Receptor:1||Progressionfree survival:1||Prominin1:1||Prostaglandin E2:1||Prostate cancer:1||Psychiatric disorder:1||RALDH2 protein:1||RNA:1||RUNX1RUNX1T1:1||Radiogenomic:1||Read mapping:1||Renal cell carcinoma:1||Resistance:1||Retinitis pigmentosa:1||Rheumatoid arthritisassociated interstitial lung disease:1||Risk score:1||Risk stratification:1||Sadenosylmethionine (SAM):1||SCLC:1||SIDRseq:1||SKG mouse:1||SYNE1:1||Sample size:1||Schizophrenia:1||Sequencing:1||Sialidosis:1||Silica:1||Single cell:1||Single cell analysis:1||Single cell genomics:1||Single nucleotide polymorphism:1||Single nucleotide variation:1||Singlecell RNASeq:1||Singlecell TCR sequencing:1||Singlecell sequencing:1||Skislope audiogram:1||Small cell lung carcinoma:1||Smart Phone:1||Smoking:1||Solid tumors:1||Somatic copy number alteration:1||Somatic mutation:1||Spastic paraplegia 11:1||Spatially resolved sequencing:1||Sporadic case:1||Squamous cell:1||Src kinase:1||Stargardtlike macular dystrophy:1||Statistical power:1||Structural variations:1||Subrenal capsule implantation:1||Substitution rate:1||T cell:1||T cell lymphoma:1||TLymphocytes:1||T790M mutation:1||TERT promoter:1||TGFB2:1||TMPRSS3 mutation:1||TMPRSS3 mutations:1||TP53 mutations:1||TRKA immunohistochemistry:1||Target:1||Target enrichment sequencing:1||Targeted panel sequencing:1||Targeted resequencing:1||Targeted resequencing:1||Telangiectasia:1||Temozolomide:1||Th17 cell activation:1||Therapy:1||Thin corpus callosum:1||Thymoma:1||Tissueresident memory T cells:1||Triple Negative Breast Neoplasms:1||Triple negative breast cancer:1||Triplenegative breast cancer:1||Triplenegative breast neoplasms:1||Tumor Biomarkers:1||Tumor Necrosis FactorAlpha:1||Tumor associated:1||Tumor evolution:1||Tumor mutational burden (TMB):1||Tumor necrosis factor inhibitor:1||Tumoral heterogeneity:1||Tumorinfiltrating immune cells:1||UMI:1||Vaccine:1||Validation Study:1||Vector:1||WDR19 gene:1||X chromosome:1||Young colorectal cancer:1||Youngonset Parkinson&apos:1||Youngonset dystonia:1||academic medicine:1||acute myeloid leukemia:1||adavosertib:1||adipose tissue:1||adiposederived stem cell:1||adoption:1||adoptive immunotherapy:1||adult Tcell leukemia:1||aging:1||alternative lengthening of telomeres:1||amyloidosis:1||angiogenesis inhibitors:1||antitumor immunity:1||apoptosis:1||arteries:1||ascites:1||asymmetric dimerization:1||atherosclerosis:1||audiological:1||auditory neuropathy spectrum disorder:1||availability:1||axoneme:1||benchmark database:1||biomarker:1||biomarkers:1||biomedical engineering:1||body composition:1||body mass index:1||brain location:1||breast cancer susceptibility gene 2:1||cancer biology:1||cancer genomics:1||cancer panel:1||cancer research:1||cancerassociated fibroblast:1||cancers:1||cell:1||cell RNA&:1||cell biology:1||cell interaction:1||cell signaling:1||cellfree DNA:1||cellular process:1||ceralasertib:1||cerebellar glioblastoma:1||cervical cancer:1||chemotherapy resistance:1||chromosomal microarray:1||chromosome translocation:1||ciliopathy:1||circulating tumor DNA:1||circulating tumor DNA (ctDNA):1||clinical genetics:1||clinical trials, phase II as topic:1||clonal hematopoiesis:1||cochlea:1||cognitive reserve:1||colorectal cancers:1||complement:1||computational biology:1||congenital anomalies of kidney and urinary tract:1||connexins:1||copy number variant:1||copy number variation:1||coronary artery disease:1||crizotinib:1||diagnostics:1||dihydrofolate reductase:1||dorsoventral organization:1||driver mutation:1||drug resistant:1||eQTL:1||emphysema:1||empowerment:1||eosinophil:1||epidermal growth factor:1||epidermal growth factor receptor:1||epidermal growth factor receptor pathway:1||exonuclease:1||fibrosis:1||fineneedle aspiration:1||focal segmental glomerulosclerosis:1||framework:1||frozen tissue:1||gammadelta Tcell receptor repertoire:1||gastric cancer:1||gastrointestinal neoplasms:1||gene array:1||gene expression:1||geneenvironment interaction:1||genetic counseling:1||genetic diversity:1||genetic risk:1||genetics:1||genome instability:1||genomewide association study:1||glialike supporting cells:1||glioblastoma multiforme:1||glioblastoma subclassification:1||global:1||glycosylphosphatidylinositol (GPI)anchorage:1||health care:1||health data:1||healthy baseline:1||hereditary:1||highthroughput DNA sequencing:1||histopathological growth pattern:1||homologous recombination:1||homologydependent recombination deficiency:1||human:1||human diversity:1||human leukocyte antigen:1||human pluripotent stem cells:1||immune cells:1||immune checkpoint:1||immune checkpoint inhibitors:1||immune complex:1||immune evasion:1||immune repertoire sequencing:1||immune signature:1||immunebased mechanisms underlying tumor radiosensitization:1||immunecheckpoint inhibitor:1||infrastructure:1||integrins:1||intercellular communication:1||lifestyle:1||liquid biopsy:1||liver:1||liver metastasis:1||low skeletal muscle mass:1||lowdepth whole genome sequencing:1||lung cancer:1||machine learning:1||macrophages:1||marginal zone lymphoma:1||matrix metalloproteinase 9:1||maturity framework:1||medulloblastoma:1||metabolism:1||metallothionein:1||metastasis:1||metastatic:1||metastatic breast cancer:1||metastatic renal cell carcinoma:1||miR374a5p:1||microRNA192:1||microarray:1||microcephaly:1||microcontact printing:1||mild to moderate sensorineural hearing loss:1||molecular biology:1||molecular features:1||molecular genetic test:1||molecular tumour board:1||monocyte:1||monogenic:1||mortality:1||mouse:1||myosteatosis:1||neoadjuvant chemotherapy:1||neutrophils:1||neversmoker female:1||next generation sequencing:1||next generation sequencing (NGS):1||nextgeneration sequencing (NGS):1||nonsmallcell lung cancer:1||nonsyndromic hearing impairment:1||nonsyndromic sensorineural hearing loss (NSHL):1||obesity:1||obesityrelated morbidities:1||occupational attainment:1||ocular:1||olaparib:1||oncogenes:1||oncology:1||ovarian cancer:1||p.A82P:1||p.P240L:1||pathogenesis:1||patientderived xenograft:1||patients:1||phenotype:1||policy makers:1||poly(ADPribose) polymerase:1||polygenic score:1||polymerase:1||poziotinib:1||precision medicine:1||proinflammatory characteristics:1||process optimization:1||progenitor cells:1||prognosis:1||programmed cell death 1 receptor:1||progressionfree survival:1||public trust:1||quality control:1||radiotherapy:1||reactive oxygen species:1||real world evidence:1||recurrent upper and lower respiratory tract infections:1||refractory diffuse large Bcell lymphoma:1||refractory metastatic breast cancer:1||relapsed diffuse large Bcell lymphoma:1||responsiveness:1||saracatinib (AZD0530):1||scRNAseq:1||senescence:1||sensorineural hearing loss:1||seq:1||sequencing:1||sex differences:1||single nucleotide variant:1||single&:1||singlecell RNAseq:1||singlecell omics:1||skeletal dysplasia:1||small cell lung cancer:1||small cell lung carcinoma:1||smoothmuscle cells:1||spinal cord organoid:1||stem cells research:1||steroidresistant nephrotic syndrome:1||subcontinental diversity:1||subcutaneous fat:1||survey:1||survival analysis:1||symmetry breaking:1||targeted sequencing:1||taxane:1||tectorial membrane:1||telomere length:1||telomere maintenance mechanism:1||tertiary lymphoid structure:1||therapeutic procedure:1||thyroid:1||thyroid cancer:1||tissue:1||transcription factor:1||transcriptome:1||trastuzumab:1||triplenegative breast cancer:1||trt1:1||tumor evolution:1||tumor heterogeneity:1||tumor immune microenvironment:1||tumor mutation burden:1||tumorinfiltrating lymphocytes:1||type 2 diabetes:1||vascular disorders:1||vessel cooption:1||visceral fat:1||vistusertib:1||wholegenome sequencing:1||“Ears of the lynx” sign:1||3Dflow path membrane filter:1||ALK fusion:1||AMPKα:1||ARID1B:1||AZD2811NP:1||AZD9291:1||Actionable genetic alteration:1||Adaptive Immunity:1||Advanced breast cancer:1||Age of onset:1||Aggressive T cell lymphoma:1||Alcohol consumption:1||Alignment tool:1||Alzheimer's disease:1||Anaplastic lymphoma kinase (ALK):1||Angioimmunoblastic Tcell lymphoma:1||Antineuronal nuclear antibody:1||Arrestin beta 1:1||Ataxiatelangiectasia:1||Atypical:1||Auditory neuropathy spectrum disorder:1||Auditory steadystate response:1||Autosomalrecessive polycystic kidney disease:1||BMI:1||BRAF:1||Background error:1||Benign prostatic hyperplasia:1||Biliary tract cancer:1||Biobanking:1||Body fat:1||Breast neoplasms:1||Ctype natriuretic peptide:1||C. elegans:1||C797S mutation:1||CANT1:1||CD47:1||CDH23:1||CHARGE syndrome:1||CHD7:1||CHM:1||CMS:1||CNV alteration:1||COCH:1||CTCs:1||CXCL1:1||CXCL13:1||CXCL13CXCR3 signaling:1||Cancer:1||Cancer Systems Biology:1||Cancer diagnosis:1||Cancer panel:1||Cancer systems biology:1||CancerSCAN:1||Carcinoma:1||Cardiovascular Disease:1||Caroli syndrome:1||Caveolin1:1||Cell isolation:1||Cerebellar:1||Chemoradiotherapy:1||Chemoresponse:1||Chimeric transcripts:1||Choroideremia:1||Chronic obstructive pulmonary disease (COPD):1||Circulating cellfree DNA:1||Circulating tumor cells(CTC):1||Clinical features:1||Clinical panel sequencing:1||Clinical trials:1||Clinico‐genomic model:1||Clusters:1||Common genetic variants:1||Comparison:1||Core gene:1||Covid19:1||CpG island methylator phenotype (CIMP):1||Crohn&apos:1||Crohn's Disease:1||Cytosine deamination errors:1||DFNA22:1||DFNB22:1||DFNB9:1||DFNX1 (Xlinked nonsyndromic sensorineural deafness type 1):1||DNA:1||DNA damage and response:1||DNA damage response:1||DNA damages:1||DNA fragmentation:1||DNA sequencing:1||DYT25:1||Deep brain stimulation:1||Desbuquois dysplasia:1||Diet:1||Diffuse large B cell lymphoma:1||Drug resistance:1||Drug response:1||Dysplastic nodules:1||EGFR Cterminal domain deletion:1||EGFR targeted therapy:1||EML4ALK:1||EMT:1||EWS:1||Earlyonset Parkinson&apos:1||Efficiency:1||Embedding:1||Endoscopic ultrasound‐guided fine needle core biopsy:1||Enhancer hijacking:1||Enzymatic conversion:1||Epidermal growth factor:1||Epidermal growth factor receptor:1||Epidermal growth factor receptor (EGFR):1||Esophageal neoplasms:1||Evaluation:1||Ewsr1:1||Exercise:1||Exosome:1||F18fluorodeoxyglucose (FDG):1||

STATISTICS: Total View:; Daily View:

RSS_1.0 RSS_2.0 ATOM_1.0

(03063) 25-2, SUNGKYUNKWAN-RO, JONGNO-GU, SEOUL, KOREA samsunglib@skku.edu

Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.

Detailed Information

Keyword

BROWSE